We therefore hypothesized that the expression of the FcγRs CD32 and/or CD64 on malignant AML cells might interfere with ADCC, by sequestering the antibody Fc in cis at the surface of CD123+FcγR+ target cells. The gene discussed is FCGR2A; the disease is acute myeloid leukemia.